CSL shares have been under pressure, trading near $180, due to softer profits, rising costs, and slow plasma business recovery. Despite recent challenges, CSL's plasma collections, vaccine business, ...
The company raised its full year revenue guidance to a reported decline of 1% to 4% and organic growth ex CSL of 7% to 10%. Hospital revenue growth guidance was updated to 4% to 7% (reported and ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する